Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DBVT vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EVMN Captures Overall Composite Edge (30.0 SELL vs 30.9 SELL), While DBVT Leads 3–2 on Growth & Valuation Pillars
EVMN Overall Winner
6-Pillar Tally: DBVT 3 – 2 EVMN (1 Tie)
Matrix Metrics: DBVT 4 – 3 EVMN
As of Nov 16, 2026, Evommune, Inc. (EVMN) captures the overall head-to-head institutional edge over DBV Technologies S.A. (DBVT) on higher Unified Composite conviction (30.0/100 SELL vs. 30.9/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DBVT wins 3–2 across the 6-pillar growth and valuation breakdown. DBVT trades at $10.27 (N/M Forward P/E, -5577.0% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While DBVT currently prints a higher short-term Unified Composite Score (30.9/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -5577.0% operating margin) and revenue trajectory (+0.0% vs. -42.9% YoY).
- Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both DBVT (30.9/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DBVT vs EVMN
DBVT
DBV Technologies S.A.
$10.27
-6.76% 1D
Market Cap
$692.2M
TTM Revenue
$3.7M
Forward P/E
N/M
Beta / 30D Vol
1.18β · 77% Vol
Unified Composite Score
30.9
SELL
Tech 15.0
Fund 36.0
Flow 60.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
EVMN
Head-to-Head Winner
Evommune, Inc.
$7.10
-6.95% 1D
Market Cap
$315.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.05β · 118% Vol
Unified Composite Score
30.0
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (DBVT 3 – 2 EVMN)
1. Valuation Multiples
DBVT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
142.9x
N/M
2. Growth & Scale
DBVT
Revenue Growth (YoY)
-42.9%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$3.7M
N/A
Market Cap
$692.2M
$315.5M
3. Profitability & Quality
EVMN
Gross Margin
100.0%
N/A
Operating Margin
-5577.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-205.8%
-69.5%
4. Balance Sheet & Cash Flow
DBVT
Cash Generation (TTM)
-$192M
-$75M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$158M Net Cash
$52M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
EVMN
Options Structure Phase
SURGE
SURGE
Current IV / %ile
64.5% (13th %ile)
209.0% (53rd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DBVT (4) vs EVMN (3)| Institutional Metric | DBVT | EVMN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $692.2M | $315.5M | DBVT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -42.9% | +0.0% | EVMN | |
| Operating Margin (TTM) | -5577.0% | 0.0% | EVMN | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -205.8% | -69.5% | EVMN | |
| 52-Week Range Position | 9% ($9–$26) | 8% ($5–$33) | DBVT | |
| Beta / 30D Volatility | 1.18β · 77% Vol | 1.05β · 118% Vol | DBVT | |
| Unified Institutional Score | 30.9 / 100 (SELL) | 30.0 / 100 (SELL) | DBVT | |
| Trailing 12M Revenue (USD) | $3.7M | N/A | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 142.9x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$192M ($158M Net Cash) | -$75M ($52M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EVMN +23.85 pp
3M Horizon
DBVT +21.04 pp
6M Horizon
DBVT +22.34 pp
1Y Horizon
DBVT +39.67 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DBVT Revenue | EVMN Revenue | DBVT Op. Margin | EVMN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | N/A | -1162.8% | N/A | DBVT |
| FY2020 | $10M | N/A | -1408.7% | N/A | DBVT |
| FY2021 | $10M | N/A | -1727.6% | N/A | DBVT |
| FY2022 | $0M | N/A | -1994.9% | N/A | DBVT |
| FY2023 | $20M | N/A | -486.0% | N/A | DBVT |
| FY2024 | $0M | $10M | -2808.7% | -1000.2% | EVMN |
| FY2025 | $10M | $10M | -2609.2% | -623.6% | EVMN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DBVT
SURGE
Current IV
64.5%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
EVMN
SURGE
Current IV
209.0%
IV Percentile
53rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DBVT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
EVMN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DBVT vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Evommune, Inc. (EVMN) captures the overall head-to-head institutional edge over DBV Technologies S.A. (DBVT) on higher Unified Composite conviction (30.0/100 SELL vs. 30.9/100 SELL) after splitting the core matrix 3–4 (led by Profitability & Quality, Options & Positioning), while DBVT wins 3–2 across the 6-pillar growth and valuation breakdown. DBVT trades at $10.27 (N/M Forward P/E, -5577.0% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DBVT currently prints a higher short-term Unified Composite Score (30.9/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -5577.0% operating margin) and revenue trajectory (+0.0% vs. -42.9% YoY). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both DBVT (30.9/100 SELL) and EVMN (30.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DBVT leads the Growth & Scale pillar: DBVT posts -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), DBVT cumulative revenue shifted +0.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, DBVT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
DBVT screens cheaper on headline valuation multiples. DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 142.9x EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DBVT (-205.8% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.18β · 77% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
EVMN vs DBVT · Reverse Pair
DBVT vs ACRS
· Sector Peer
DBVT vs ASMB
· Sector Peer
DBVT vs SLDB
· Sector Peer
EVMN vs MPLT
· Sector Peer
EVMN vs ALMS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem